Bicycle Therapeutics has filed a patent for a method to determine the extent of cyclisation of a peptide ligand on a genetic display system. The method involves exposing the polypeptide to a molecular scaffold, removing unreacted scaffold, and measuring the unconjugated reactive group on the peptide ligand using a probe. GlobalData’s report on Bicycle Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bicycle Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bicycle Therapeutics's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Method for determining cyclisation extent of peptide ligand
See Also:
A patent application (Publication Number: US20240018508A1) describes a method for determining the extent of cyclisation of a peptide ligand displayed on a genetic display system. The method involves exposing a polypeptide displayed on the genetic display system to a molecular scaffold, removing unreacted scaffold, and then exposing the peptide ligand to probes that bind to unconjugated reactive groups on the ligand. By measuring these reactive groups, the extent of cyclisation can be determined. The probes used in the method can produce signals to indicate the presence of unconjugated reactive groups on the peptide ligand, allowing for accurate analysis.
Furthermore, the method can involve multiple probes and signalling groups to provide a detailed assessment of the cyclisation process. For instance, the probes can trigger chemiluminescent or fluorescent signals based on the presence of specific reactive groups on the peptide ligand. Additionally, the genetic display system can be combined with a purification resin before the cyclisation analysis, and the system can be eluted from the resin after the process. The peptide ligand may contain loops of amino acids between reactive residues, and the molecular scaffold used can be selected from specific options. Overall, the method offers a comprehensive approach to evaluating cyclisation in peptide ligands displayed on genetic systems, with potential applications in drug development and molecular biology research.
To know more about GlobalData’s detailed insights on Bicycle Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
